RE:BioNTech reports on early solid tumor CAR-T cell therapyOctober 23, 2023 - At the European Society for Medical Oncology Congress (ESMO) , BioNTech detailed signs of clinical activity with BNT211 and a persistence of CAR-T cells when combined with CARVac, the biotech’s RNA vaccine that’s designed to boost efficacy of the CAR-T cells. BNT211 targets the antigen Claudin-6 (CLDN6), which occurs in many solid tumors including ovarian cancer, sarcoma, testicular cancer, endometrial cancer and gastric cancer. The trial tested four dose levels with BNT211 alone or with CARVac. An overall response rate of 45% was seen in 38 of the 44 evaluable patients, plus a disease control rate of 74%.
https://www.fiercebiotech.com/biotech/esmo-biontechs-new-car-t-manufacturing-process-boosts-potency-and-side-effects-too